NewCo Shift Dialogs, in partnership with EY
Massive data problems plus massive markets mean a big opportunity for companies like Color Genomics

Health care is a multi-trillion dollar market awash in data, but thanks to regulatory and political sclerosis, it’s been a difficult sector for NewCos to gain a foothold. But that hasn’t stopped a new wave of startups from trying, and perhaps the most interesting are focusing on the intersection of genomics, lethal disease, and preventative testing. We covered Grail Bio last year, and for this week’s Shift Dialogs, we speak with Elad Gil, a co-founder of Color Genomics, which like Grail is working on new approaches to battling cancer. And as Gil explains in our interview, there’s far more potential for Color’s services than just cancer detection — as genomic testing costs scale toward zero, the potential for saving lives scales up. Below is the interview in both video and text, edited for length and clarity.
John Battelle: Welcome, Elad. To start, what’s Color Genomics founding mythology? How did you and your co-founders come up with this idea?
Read More